NeuroPace (NASDAQ:NPCE – Get Rating) had its target price hoisted by investment analysts at Morgan Stanley from $2.50 to $4.50 in a note issued to investors on Friday, Benzinga reports. The firm currently has an “underweight” rating on the stock. Morgan Stanley’s price target would indicate a potential upside of 9.76% from the company’s current price.
Separately, Lake Street Capital initiated coverage on NeuroPace in a research report on Wednesday, February 22nd. They set a “buy” rating and a $10.00 price objective for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, NeuroPace presently has a consensus rating of “Hold” and a consensus target price of $9.70.
NeuroPace Price Performance
NPCE stock opened at $4.10 on Friday. NeuroPace has a 52-week low of $1.22 and a 52-week high of $9.54. The company has a quick ratio of 10.17, a current ratio of 11.08 and a debt-to-equity ratio of 1.20. The stock has a market cap of $102.10 million, a price-to-earnings ratio of -2.14 and a beta of 2.61. The business has a fifty day moving average of $3.47 and a two-hundred day moving average of $3.10.
Institutional Inflows and Outflows
NeuroPace, Inc operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely.
- Get a free copy of the StockNews.com research report on NeuroPace (NPCE)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.